Literature DB >> 17114345

MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling.

Jian Ren1, Deepak Raina, Wen Chen, Guilan Li, Lei Huang, Donald Kufe.   

Abstract

Activation of the fibroblast growth factor (FGF) receptor 3 (FGFR3) has been linked to the development of human cancers by mechanisms that are not well understood. The MUC1 oncoprotein is aberrantly overexpressed by certain hematologic malignancies and most human carcinomas. The present studies show that MUC1 associates with FGFR3. Stimulation of cells with FGF1 increased the interaction between MUC1 and FGFR3. FGF1 stimulation also induced c-Src-dependent tyrosine phosphorylation of the MUC1 cytoplasmic domain on a YEKV motif. FGF1-induced tyrosine phosphorylation of MUC1 was associated with increased binding of MUC1 to beta-catenin and targeting of MUC1 and beta-catenin to the nucleus. FGF1 also induced binding of MUC1 to the heat shock protein 90 (HSP90) chaperone by a mechanism dependent on phosphorylation of the YEKV motif. Notably, beta-catenin and HSP90 compete for binding to the MUC1 cytoplasmic domain, indicating that MUC1 forms mutually exclusive complexes with these proteins. The results also show that inhibition of HSP90 with geldanamycin or 17-(allylamino)-17-demethoxygeldanamycin attenuates FGF1-induced binding of MUC1 to HSP90 and targeting of MUC1 to the mitochondrial outer membrane. These findings indicate that FGF1 induces phosphorylation of MUC1 on YEKV and thereby activates two distinct pathways: (a) nuclear localization of MUC1 and beta-catenin and (b) delivery of MUC1 to mitochondria by HSP90.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17114345      PMCID: PMC3322466          DOI: 10.1158/1541-7786.MCR-06-0204

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  61 in total

Review 1.  Heat shock protein 90 as a molecular target for cancer therapeutics.

Authors:  Jennifer S Isaacs; Wanping Xu; Len Neckers
Journal:  Cancer Cell       Date:  2003-03       Impact factor: 31.743

Review 2.  The ins and outs of APC and beta-catenin nuclear transport.

Authors:  Beric R Henderson; Francois Fagotto
Journal:  EMBO Rep       Date:  2002-09       Impact factor: 8.807

3.  Cell-associated episialin is a complex containing two proteins derived from a common precursor.

Authors:  M J Ligtenberg; L Kruijshaar; F Buijs; M van Meijer; S V Litvinov; J Hilkens
Journal:  J Biol Chem       Date:  1992-03-25       Impact factor: 5.157

4.  MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion.

Authors:  Joyce A Schroeder; Melissa C Adriance; Melissa C Thompson; Todd D Camenisch; Sandra J Gendler
Journal:  Oncogene       Date:  2003-03-06       Impact factor: 9.867

5.  Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein.

Authors:  Yongqing Li; Wei-Hsuan Yu; Jian Ren; Wen Chen; Lei Huang; Surender Kharbanda; Massimo Loda; Donald Kufe
Journal:  Mol Cancer Res       Date:  2003-08       Impact factor: 5.852

6.  Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen.

Authors:  L Perey; D F Hayes; P Maimonis; M Abe; C O'Hara; D W Kufe
Journal:  Cancer Res       Date:  1992-05-01       Impact factor: 12.701

7.  Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer.

Authors:  María V Croce; Marina T Isla-Larrain; Carina E Rua; Martín E Rabassa; Sandra J Gendler; Amada Segal-Eiras
Journal:  J Histochem Cytochem       Date:  2003-06       Impact factor: 2.479

8.  DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7.

Authors:  Yongqing Li; Wen Chen; Jian Ren; Wei-Hsuan Yu; Quan Li; Kiyotsugu Yoshida; Donald Kufe
Journal:  Cancer Biol Ther       Date:  2003 Mar-Apr       Impact factor: 4.742

9.  Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress.

Authors:  Li Yin; Yongqing Li; Jian Ren; Hiroaki Kuwahara; Donald Kufe
Journal:  J Biol Chem       Date:  2003-06-25       Impact factor: 5.157

10.  Human DF3/MUC1 carcinoma-associated protein functions as an oncogene.

Authors:  Yongqing Li; Derek Liu; Dongshu Chen; Surender Kharbanda; Donald Kufe
Journal:  Oncogene       Date:  2003-09-04       Impact factor: 9.867

View more
  43 in total

Review 1.  Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.

Authors:  Partha Mukhopadhyay; Subhankar Chakraborty; Moorthy P Ponnusamy; Imayavaramban Lakshmanan; Maneesh Jain; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-01-26

Review 2.  Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.

Authors:  S Bafna; S Kaur; S K Batra
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

Review 3.  Recent insights into cerebral cavernous malformations: a complex jigsaw puzzle under construction.

Authors:  Eva Faurobert; Corinne Albiges-Rizo
Journal:  FEBS J       Date:  2010-01-22       Impact factor: 5.542

4.  MUC1 oncoprotein is a druggable target in human prostate cancer cells.

Authors:  Maya Datt Joshi; Rehan Ahmad; Li Yin; Deepak Raina; Hasan Rajabi; Glenn Bubley; Surender Kharbanda; Donald Kufe
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

5.  Binding of the sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of β-catenin and subsequent cell growth.

Authors:  Shuhei Tanida; Kaoru Akita; Akiko Ishida; Yugo Mori; Munetoyo Toda; Mizue Inoue; Mariko Ohta; Masakazu Yashiro; Tetsuji Sawada; Kosei Hirakawa; Hiroshi Nakada
Journal:  J Biol Chem       Date:  2013-09-17       Impact factor: 5.157

6.  MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Subhankar Chakraborty; Subhash C Chauhan; Sangeeta Bafna; Jane L Meza; Pankaj K Singh; Michael A Hollingsworth; Parmender P Mehta; Surinder K Batra
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

7.  MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway.

Authors:  Deepak Raina; Rehan Ahmad; Dongshu Chen; Shailendra Kumar; Surender Kharbanda; Donald Kufe
Journal:  Cancer Biol Ther       Date:  2008-12-09       Impact factor: 4.742

8.  MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8.

Authors:  Naoki Agata; Rehan Ahmad; Takeshi Kawano; Deepak Raina; Surender Kharbanda; Donald Kufe
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

9.  Using LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling.

Authors:  Julie M Kneller; Thomas Ehlen; Jasenka P Matisic; Dianne Miller; Dirk Van Niekerk; Wan L Lam; Marco Marra; Rebecca Richards-Kortum; Michelle Follen; Calum Macaulay; Steven J M Jones
Journal:  Biomark Insights       Date:  2007-12-11

Review 10.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.